Open an account

Baudax Bio

BXRXQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket open · · Delayed 15 min
No price history for this range.

About BXRXQ

Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. The company is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. The company is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

Employees
9
Headquarters
Malvern, Pennsylvania
Listed
Nov 14, 2019
Sector
Health Care
Industry
Pharmaceuticals
Website
baudaxbio.com

BXRXQ key statistics

Market cap
44
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
27.25K
Volume
15
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

Baudax Bio (BXRXQ) at a glance

Baudax Bio (BXRXQ) last traded at $0.00, with a market cap of 44 and a price-to-earnings ratio of 0.00.

Volume so far is 15 shares, below the average of 27.25K shares a day.

Over the past year Baudax Bio has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

Baudax Bio met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY23 it reported -$0.30 per share against an estimate of -$0.5459.

BXRXQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 163.2% on average.

  1. Q4 FY21: reported $401.20 per share against an estimate of $60.77
  2. Q1 FY22: reported -$126.80 per share against an estimate of -$76.22
  3. Q2 FY22: reported -$42.00 per share against an estimate of -$52.32
  4. Q3 FY22: reported -$26.40 per share against an estimate of -$21.84
  5. Q4 FY22: reported -$12.33 per share against an estimate of -$10.05
  6. Q1 FY23: reported -$3.91 per share against an estimate of $5.92
  7. Q2 FY23: reported -$1.52 per share against an estimate of -$2.10
  8. Q3 FY23: reported -$0.30 per share against an estimate of -$0.5459

Similar companies

Companies in the same industry as Baudax Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.